Evidence review
How to Tell a Peptide Claim Is Outrunning Its Evidence
Twelve tells, each with a real case from the registry or the literature. Overstated peptide claims tend to fail on one of them, and usually the same one.
The shape of the problem
Almost nobody lies about peptides outright. The claims that mislead are usually assembled from true statements about a slightly different thing — a different species, a different molecule, a different route, a different indication, or a different endpoint.
What follows is a list of the specific substitutions, each with a case you can check.
Tell 1: the species swap
The claim is about people. The evidence is about rodents.
A 2026 review of injectable peptide therapy for orthopaedic and sports medicine physicians found that thymosin beta-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, and in the same breath that human orthopaedic data are lacking1.
The preclinical half travels; the second half rarely does. When a claim's citations are all animal work, the honest sentence is "this has been shown in animals", and that sentence sells much less.
Tell 2: the molecule swap
TB-500 is N-acetylated LKKTETQ — the seven-residue segment at positions 17 to 23 of thymosin beta-4. Thymosin beta-4 is a 43-residue protein. A 2026 review lists them as separate entries2.
Decades of research on the protein is not decades of research on the fragment. Our TB-500 page keeps the two apart line by line, because a page that lets them blur is useless.
Tell 3: the route swap
The published phase 3 evidence for thymosin beta-4 is an ophthalmic solution instilled in an eye, in 18 patients with neurotrophic keratopathy, with the primary healing comparison reported at p = 0.06563.
A result from an eye drop is not evidence for a subcutaneous injection into a hamstring. Route is part of the claim.
Tell 4: the indication swap
A ClinicalTrials.gov search for ipamorelin returned 3 studies in August 2026. One completed phase 2 trial studied post-operative ileus in 117 participants4. The other studied recovery of gastrointestinal function after bowel resection in 3205.
Neither studied growth hormone secretion or body composition. A compound can have a real trial history that has nothing to do with what it is discussed for.
Tell 5: the tier swap
A marker moved, and the claim is about an outcome. Inflammation markers, IGF-1, body composition on a scan — all real measurements, none of them an event.
Converting a marker into an outcome takes a trial like SELECT: 17,604 patients, a mean 39.8 months of follow-up, and a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke — 6.5% versus 8.0%, hazard ratio 0.80, 95% CI 0.72 to 0.906. That is what the upgrade costs. The full argument is in surrogate endpoints.
Tell 6: the endpoint swap
The number in the headline is not the trial's primary endpoint.
The retatrutide phase 2's declared primary was percent change in body weight at week 24, where the 12 mg arm showed −17.5% against −1.6%. The widely quoted −24.2% is the 48-week figure, a secondary endpoint7.
Both numbers are real and the trial reported both. Quoting the secondary as though it were the finding is the move worth catching — see what a phase 2 result means.
Tell 7: the phase halo
"Phase 3" sounds like the end of the argument. The thymosin beta-4 phase 3 above enrolled 18 people3. STEP 1, also a phase 3, enrolled 1,961.
Phase is a stage, not a size and not a quality grade. What size actually buys is set out in why n=30 is not n=3,000.
Tell 8: the plan quoted as a result
A registered trial is a filing, not a finding.
The BPC 157 hamstring trial, NCT07437547, was first posted in February 2026 with an estimated primary completion of February 2027 and an estimated study completion of February 20288. No result from it can exist in August 2026. Any claim resting on it is resting on a protocol — the reading method is in how to read a record.
Tell 9: the silence
Completed trials that never reported are not neutral. ARISE-3, a phase 3 of a thymosin beta-4 ophthalmic solution with 700 participants, completed its primary endpoint in November 2020 and had no results posted on ClinicalTrials.gov as of August 20269.
Whether that silence means anything is unknowable in any single case. Whether it is common is measurable, and it is: see registered but never reported.
Tell 10: the unbounded universal
"No studies show harm." "Nothing has ever been reported." "Clinically proven."
These cannot be sourced, because no search establishes a universal negative. The repairable version names the search, the count and the date — "a ClinicalTrials.gov search for X returned N studies in August 2026, and none lists Y".
If a claim cannot be rewritten in that form, it is not a claim about evidence.
Tell 11: the identity gap
A protocol is being discussed for a substance nobody has characterised.
An analytical study of products sold online as TB500 and TB1000 reported that their content is not systematically consistent with the products' own former descriptions10. And FDA's published notes on peptides nominated for compounding repeatedly cite possible immunogenicity risk from aggregation and peptide-related impurities, with added complexity in characterising the active ingredient11.
When the material is unestablished, everything downstream of it is provisional — which is why what a certificate of analysis proves is a narrower list than people expect.
Tell 12: the disclaimer that contradicts the pitch
A product described as being for research use, discussed alongside an injection schedule for a person.
"Research chemical" is not a regulatory category. FDA's compounding framework evaluates substances as nominations to the 503A and 503B bulks lists, and publishes the safety concerns it identifies for each — a process with no tier called "research use"11. The phrase is doing something else, and what it is doing is worth knowing.
Six questions that settle most of it
What species was it in?
What exact molecule, by what route, in whom?
Is the quoted number the declared primary endpoint, at the declared timepoint?
How many people, and is that enough to see what is being claimed?
Was it blinded, and does that matter for this endpoint? Sometimes it does not — see open-label vs blinded.
Who paid, and did the results get posted? Both are one click away, and both are informative.
What a strong claim looks like
For contrast, here is one that survives every tell above. Semaglutide, in humans, by the studied route, in a named population, at the declared primary endpoint, blinded, in 17,604 people, sponsored by a company that posted and published the result, measuring events rather than markers6.
That is the standard. Very little of what is sold as a peptide is supported by anything of that shape, and saying so plainly is not scepticism — it is the accurate description. Our injury recovery and weight loss pages apply the same tests compound by compound, and the rest of this cluster lives in research.
Frequently asked questions
What is the most common way a peptide claim overstates its evidence?
Substitution. The claim is about humans and the evidence is about rodents; or about an injection and the evidence is an eye drop; or about one molecule and the evidence is about a longer protein containing it. Each substitution is individually small and each is checkable against the cited source.
How should an absence of evidence be stated?
With a named search, a count and a date. 'A ClinicalTrials.gov search for ipamorelin returned 3 studies in August 2026, and neither of the two completed phase 2 trials studied growth hormone secretion' is checkable. 'No studies show harm' is not, because no search can establish a universal negative.
Does a registered trial mean a compound has evidence behind it?
No. NCT07437547, a phase 2 trial of BPC 157 for hamstring strain, was first posted in February 2026 with an estimated primary completion of February 2027 and study completion of February 2028. A registration is a plan, and no result from that trial can exist yet.
What does a claim that survives all these tests look like?
SELECT is the example: semaglutide in 17,604 humans with pre-existing cardiovascular disease, blinded, at the declared primary endpoint, measuring events rather than markers — 6.5% versus 8.0% for a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, hazard ratio 0.80 (95% CI 0.72 to 0.90). Very few peptide claims are built on anything of that shape.
References
- Mayfield CK et al (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. https://pubmed.ncbi.nlm.nih.gov/41476424/
- Mendias CL; Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. https://pubmed.ncbi.nlm.nih.gov/41966639/
- Sosne G et al (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. https://pubmed.ncbi.nlm.nih.gov/36613994/
- U.S. National Library of Medicine (2017). NCT00672074 — Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00672074
- U.S. National Library of Medicine (2017). NCT01280344 — Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT01280344
- Lincoff AM et al (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Jastreboff AM et al (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/37366315/
- U.S. National Library of Medicine (2026). NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437547
- U.S. National Library of Medicine (2022). NCT03937882 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03937882
- Delcourt V et al (2023). TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. https://pubmed.ncbi.nlm.nih.gov/36482504/
- U.S. Food and Drug Administration (2026). Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Amylin Analogs: The Next Class After Incretins
An amylin analog has been FDA-approved since 2005. What changed is not the hormone — it is how long the molecule lasts. The trials, in order.
ReadCertificates of Analysis: What They Prove
A COA is a claim about a lot, not a guarantee about a vial. What each test answers, what a purity figure cannot say, and the gap the document never closes.
ReadCompounded Is Not the Trial Drug
A trial tests one defined article: a molecule, a form, a concentration, a container. Compounding changes some of those, and the evidence travels only that far.
Read503A vs 503B: What Is Actually in the Vial
One scheme is inspected against manufacturing standards; the other is not. What each may legally start from, and what the inspection record shows in practice.
ReadGrowth-Hormone Secretagogues: What the Evidence Actually Shows
These compounds reliably raise IGF-1. That is the surrogate. When trials measured function, fracture recovery or disease progression, the results changed.
ReadHealing Peptides and the Gap Between Anecdote and Trial
BPC-157 and TB-500 have thirty years of animal work and a very thin human record. Here is exactly what is registered, what is published, and what neither shows.
ReadHow to Read a ClinicalTrials.gov Record
A registration is a filing, not a review. Fifteen fields, two real peptide records, and the specific places where a record quietly tells you it has stalled.
ReadIncretins Explained: GLP-1, GIP and Glucagon
Three hormones, three receptors, and a class of drugs built on them. What each one does, and why the receptor diagram predicts less than it looks like.
ReadMuscle During Rapid Weight Loss: What Has Been Measured
Roughly a quarter of the weight lost is lean mass — and that was true on placebo too. What the DXA substudies actually show, and how small they are.
ReadOpen-Label vs Blinded: What You Can Conclude
Masking is not a quality score — it decides which explanations a trial can rule out. Five real registry records, and the honest evidence on blinding itself.
ReadOral vs Injectable Peptides: What Changes
One molecule, two routes, one label — and roughly 73 times the milligrams per week. What the gut does to a peptide, and what it costs to get past it.
ReadHalf-Life and Dosing Frequency
From 1.5 minutes to a week, on labels for the same hormone family. Half-life is the number that decides whether a peptide is dosed before meals or once a month.
ReadReconstitution: The Arithmetic, Not the Advice
Concentration is mass divided by volume — except the naive division is wrong, and an FDA label's own numbers prove it. The maths, and what it cannot tell you.
ReadWhat a Phase 2 Result Does and Does Not Tell You
Phase 2 is a dose-finding experiment, not a verdict. Two peptide programmes where the phase 3 exists show exactly which parts of the number survive.
ReadRegistered but Never Reported: The Trials That Vanish
Completed trials that post no results are common and measurable. How to check a compound's registry file, and what the silence does and doesn't tell you.
ReadWhy n=30 Is Not the Same as n=3,000
Enrolment size is not a quality badge — it is precision, and it is the ability to see rare harm. Worked on real peptide trials, with the arithmetic shown.
ReadSurrogate Endpoints vs Outcomes That Matter
Most peptide claims rest on a marker moving, not on anything happening to a person. Two paired trials show what the difference costs to establish.
ReadWhy a Triple Agonist Is Not Simply Better Than a Dual
Adding a receptor adds a mechanism, a side-effect profile, and a reason a trial might read differently. The numbers do not rank the way the labels suggest.
ReadWhat a Peptide Is, and What the Word Hides
Three amino acids or sixty-three thousand daltons — both get called peptides. The definitional confusions that cause the most misreading, settled by labels.
ReadWhat “Research Chemical” Actually Means
The phrase is a sales category, not a regulatory one. What FDA has actually published about seventeen of these peptides, and what the label is doing instead.
ReadWhat Happens When a Peptide Trial Fails
Four negative results, and what each one killed. A trial can fail an indication, a molecule, a surrogate, or nothing at all — and the difference matters.
ReadWho Funded the Trial, and Why It Matters
Sponsorship shifts conclusions more than it shifts methods. Where to find the funding line, what the Cochrane evidence measured, and what it did not.
ReadWhy Most Peptide Trials Are Small and Short
A registry census, August 2026: one compound has 759 registered studies, another has zero. The reasons are economic, not about whether the drug works.
Read